Previous 10 | Next 10 |
MediWound (MDWD) announces that the U.S. FDA has declined to approve the company's NexoBrid treatment for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.The health regulator said that it had completed its review of the BLA, as amended, a...
YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter (CRL) from the U...
Siriporn Lin/iStock via Getty Images MediWound (MDWD) rose sharply in the pre-market after its partner Kaken Pharmaceutical (SKKAF) announced that it submitted a new drug application for approval of topical burn therapy KMW-1 in Japan. The new drug application to the Ministry of Hea...
Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The earnings calendar is light next week as the first half of the year comes to a close, but Micron (NASDAQ:MU), General...
MediWound (MDWD) completes patient enrollment for the interim assessment of its U.S. EscharEx Phase 2 study for the treatment of venous leg ulcers ((VLUs)).The company said that the interim assessment, meant for futility analysis and potential sample size adjustment, is expected by ...
YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the enrollment target of patients for an interim assessme...
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrat...
The following slide deck was published by MediWound Ltd. in conjunction with this event. For further details see: Mediwound (MDWD) Investor Presentation - Slideshow
MediWound (MDWD): Q1 GAAP EPS of -$0.10 beats by $0.02.Revenue of $5.85M (+31.8% Y/Y) beats by $0.32M.Press Release For further details see: MediWound EPS beats by $0.02, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...